Sandbox Reserved 430: Difference between revisions

2. Savi, P., et al. "P2Y 12, a new platelet ADP receptor, target of clopidogrel." Biochemical and biophysical research communications 283.2 (2001): 379-383. <ref>http://www.sciencedirect.com/science/article/pii/S0006291X01948168</ref>

3. Coon, Minor J. "Cytochrome P450: nature's most versatile biological catalyst." Annu. Rev. Pharmacol. Toxicol. 45 (2005): 1-25. <ref>http://www.annualreviews.org/doi/abs/10.1146/annurev.pharmtox.45.120403.100030</ref>

4. Gurbel, Paul A., et al. "Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity." Circulation 107.23 (2003): 2908-2913. <ref>http://circ.ahajournals.org/content/107/23/2908.full</ref>

5. Barn, Kulpreet, and Steven R. Steinhubl. "A brief review of the past and future of platelet P2Y12 antagonist." Coronary artery disease 23.6 (2012): 368-374. <ref>http://journals.lww.com/coronary-artery/Abstract/2012/09000/A_brief_review_of_the_past_and_future_of_platelet.2.aspx</ref>

6. Bodin, Philippe, and Geoffrey Burnstock. "Purinergic signalling: ATP release." Neurochemical research 26.8-9 (2001): 959-969. <ref>http://link.springer.com/article/10.1023%2FA%3A1012388618693#page-1</ref>